Publication:
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

No Thumbnail Available

Date

2014-07-01T00:00:00Z

Authors

Authors

Ozaras, Resat
Mete, Bilgul
Ceylan, Bahadir
Ozgunes, Nail
Gunduz, Alper
Karaosmanoglu, Hayat
Cagatay, Atahan
Gokturk, Kadir
Erdem, Levent
Kocak, Funda

Journal Title

Journal ISSN

Volume Title

Publisher

Research Projects

Organizational Units

Journal Issue

Metrics

Search on Google Scholar

Abstract

Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.

Description

Keywords

Citation

Ozaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., Cagatay A., Gokturk K., Erdem L., Kocak F., et al., -First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment-, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, ss.774-780, 2014
Page Views

0

File Downloads

0

Sustainable Development Goals